Merck KGaA Stock
€107.50
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merck KGaA | -1.550% | -2.671% | -15.487% | -20.429% | -12.101% | -36.783% | -19.415% |
| Bayer AG | -1.680% | 5.546% | -16.107% | 68.007% | 3.920% | -31.638% | -27.622% |
| AbbVie Inc. | -1.740% | -2.725% | -1.128% | -1.118% | -1.833% | 36.216% | 113.086% |
| Johnson & Johnson | 0.360% | 1.907% | 2.976% | 40.565% | 19.441% | 46.191% | 58.222% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.
Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.
Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.
Comments
News
3 Undervalued Names Too Cheap to Ignore
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, some fairly sizable firms are trading
Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades
Over the past year, Merck's (NYSE: MRK) shares have climbed by 46%. That seems a bit surprising. Last year, the company's financial results were relatively weak as it faced declining revenue for one
Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement?
If you're at all interested in the pharmaceutical sector, you may be overwhelmed by the opportunity for GLP-1 weight-loss therapies. Sure, that's an important new drug category, but it isn't the